Cellectis to showcase gene therapy potential at ESGCT conference.

Cellectis, a clinical-stage biotech company, will present data at the European Society of Cell and Gene Therapy conference, highlighting the potential of single-stranded DNA (ssDNA) as a universal non-viral gene delivery matrix and an in-depth study of off-target effects of TALE Base Editors (TALEBs) in the genome. The presentation will be given by Julien Valton, Vice President of Gene Therapy at Cellectis, on October 8th.

Cellectis, a clinical-stage biotechnology company specializing in gene-editing technologies, will present significant findings at the European Society of Cell and Gene Therapy (ESGCT) annual congress. The presentations, scheduled for October 7-10, 2025, in Sevilla, Spain, highlight the potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral gene delivery matrix and an in-depth study of off-target effects of TALE Base Editors (TALEBs) in the genome.

Non-Viral Gene Delivery with CssDNA

Julien Valton, Vice President of Gene Therapy at Cellectis, will present data on October 8, 2025, from 2:00 p.m. to 3:30 p.m. CET, titled "Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing" Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress^[1]. The research showcases the strong potential of CssDNA as a universal and efficient non-viral DNA template for gene therapy applications. This development expands the scope of non-viral DNA template delivery from gene corrections to broader therapeutic applications.

TALE Base Editors: Safety and Potential

On October 9, 2025, from 2:00 p.m. to 3:30 p.m. CET, Maria Feola, Senior Scientist and Team Leader Gene Editing at Cellectis, will present "Comprehensive analysis of TALEB off-target editing" Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress^[1]. This study investigates potential off-target effects of TALEB in the nuclear genome of primary T cells. The research found no evidence of biases towards off-site C-to-T editing at sites flanked by CTCF binding sites, providing a strong framework for the safe development of TALEB in therapeutic cell engineering.

About Cellectis

Cellectis is a biotechnology company that uses its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. For more information, visit www.cellectis.com Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress^[1].

References

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress^[1] https://www.stocktitan.net/news/CLLS/cellectis-to-present-data-on-non-viral-gene-therapy-and-tale-base-e9xwtd5hbtvt.html